Literature DB >> 1906084

Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease.

M C Cheung1, B G Brown, A C Wolf, J J Albers.   

Abstract

Plasma high density lipoproteins (HDL) can be separated into two subpopulations of apolipoprotein A-I-containing particles: those that also contain apoA-II [Lp(AI w AII)] and those that do not [Lp(AI w/o AII)]. These particles were isolated by immunoaffinity chromatography from 17 men (9 normolipidemic (NL), 8 hyperlipidemic (HL) with symptomatic coronary artery disease (CAD), from 17 NL men without any symptoms of CAD (healthy controls), and from 10 NL men with entirely normal coronary arteriograms (CAD-free controls). The distributions of particle size in these two subpopulations were determined by gradient gel electrophoresis and densitometric scanning. Approximately half of the Lp(AI w AII) particles in all subjects were distributed in the 8.2-9.2 nm interval. For patients with CAD, a greater fraction of the particles were small, in the 7.0-8.2 nm interval [33% in CAD vs. 26% in CAD-free controls (P less than 0.01) and 19% in healthy controls (P less than 0.0001)], and a smaller fraction of the particles were in the 9.2-11.2 nm interval (14% in CAD vs. 24% in CAD-free control (P less than 0.002) and healthy control groups (P less than 0.001). The Lp(AI w/o AII) of both control groups were primarily composed of two discrete subpopulations in the 8.2-9.2 nm and the 9.2-11.2 nm intervals. In CAD patients there were fewer particles in the 9.2-11.2 nm size interval (23% in CAD vs. 33% in CAD-free controls (P less than 0.005) and 36% in healthy controls (P less than 0.0001), and more particles in the smallest 7.0-8.2 nm size interval (32% in CAD vs. 23% in CAD-free controls (P less than 0.01) and 18% in healthy controls (P less than 0.001]. Thus, the spectrum of HDL particle sizes in patients with CAD tends to be shifted toward the smaller particle when compared with the two control groups. This was observed in both NL and HL patients with HDL cholesterol (CH) values in the normal range. As a group, CAD patients had lower HDL (42 +/- 7 mg/dl) and HDL2 (6 +/- 4 mg/dl) CH than healthy (HDL: 49 +/- 7, HDL2: 12 +/- 6 mg/dl) and CAD-free (HDL: 51 +/- 9, HDL2: 12 +/- 6 mg/dl) controls. When controls and patients were compared for their frequencies of abnormal HDL CH levels and particle sizes, abnormalities in HDL and HDL2 CH levels were not significantly more frequent (twofold) among CAD patients than among controls.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906084

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  31 in total

1.  Clinical applications of advanced lipoprotein testing in diabetes mellitus.

Authors:  Danyaal S Moin; Anand Rohatgi
Journal:  Clin Lipidol       Date:  2011-08-01

Review 2.  The physiology of lipoproteins.

Authors:  Thomas N Tulenko; Anne E Sumner
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

3.  Reduced growth hormone secretion in obesity is associated with smaller LDL and HDL particle size.

Authors:  Hideo Makimura; Meghan N Feldpausch; Takara L Stanley; Noelle Sun; Steven K Grinspoon
Journal:  Clin Endocrinol (Oxf)       Date:  2012-02       Impact factor: 3.478

4.  The isolation and characterization of high-density-lipoprotein subfractions containing apolipoprotein E from human plasma.

Authors:  H M Wilson; B A Griffin; C Watt; E R Skinner
Journal:  Biochem J       Date:  1992-06-01       Impact factor: 3.857

5.  Apolipoprotein A-II alters the proteome of human lipoproteins and enhances cholesterol efflux from ABCA1.

Authors:  John T Melchior; Scott E Street; Allison B Andraski; Jeremy D Furtado; Frank M Sacks; Rebecca L Shute; Emily I Greve; Debi K Swertfeger; Hailong Li; Amy S Shah; L Jason Lu; W Sean Davidson
Journal:  J Lipid Res       Date:  2017-05-05       Impact factor: 5.922

6.  Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence.

Authors:  B Greg Brown; Xue-Qiao Zhao; Marian C Cheung
Journal:  J Clin Lipidol       Date:  2007-02-15       Impact factor: 4.766

Review 7.  Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism.

Authors:  John J Albers; Simona Vuletic; Marian C Cheung
Journal:  Biochim Biophys Acta       Date:  2011-06-28

8.  Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography.

Authors:  Milada Dobiásová; Jiri Frohlich; Michaela Sedová; Marian C Cheung; B Greg Brown
Journal:  J Lipid Res       Date:  2011-01-11       Impact factor: 5.922

9.  The impact of plasma triglyceride and apolipoproteins concentrations on high-density lipoprotein subclasses distribution.

Authors:  Li Tian; Yanhua Xu; Mingde Fu; Tao Peng; Yinghui Liu; Shiyin Long
Journal:  Lipids Health Dis       Date:  2011-01-21       Impact factor: 3.876

Review 10.  Dietary fats and health: dietary recommendations in the context of scientific evidence.

Authors:  Glen D Lawrence
Journal:  Adv Nutr       Date:  2013-05-01       Impact factor: 8.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.